icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Once-Daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in Combination With Peginterferon Alfa-2b/Ribavirin (PR) for 12 Weeks Plus 12 Weeks PR in Treatment-Naive Patients With HCV Genotype 1 (G1): SVR Results From NEXT-1, a Phase 2 Study
 
 
  Reported by Jules Levin
AASLD Nov 5-8 2011 SF
 
J. Vierling,1 F. Poordad,2 E. Lawitz,3 R. Ghalib,4 W. M. Lee,5 N. Ravendhran,6 J. Galati,7 B. Bacon,8 S. Flamm,9 L. Balart,10 B. Freilich,11 E. Schiff,12 I. Jacobson,13 P. Kwo,14 S. Gordon,15 M. Sulkowski,16 R. Jiang,17 N. Boparai,17 E. Chaudhri,17 M. Treitel,17 E. Hughes,18 C. Brass,18 J. Albrecht18 1Baylor College of Medicine, Houston, TX; 2Cedars-Sinai Medical Center, Los Angeles, CA; 3Alamo Medical Research, San Antonio, TX; 4The Liver Institute at Methodist Dallas, Dallas, TX; 5University of Texas Southwestern Medical Center, Dallas, TX; 6Digestive Disease Associates, Baltimore, MD; 7Liver Specialists of Texas, Houston, TX; 8Saint Louis University School of Medicine, St. Louis, MO; 9Northwestern Feinberg School of Medicine, Chicago, IL; 10Tulane University Health Sciences Center, New Orleans, LA; 11Kansas City Gastroenterology and Hepatology, Kansas City, MO; 12University of Miami Center for Liver Diseases, Miami, FL; 13Weill Cornell Medical College, New York, NY; 14Indiana University School of Medicine, Indianapolis, IN; 15Henry Ford Hospital, Detroit, MI; 16Johns Hopkins Rockland Physicians Practice and Research Group, Greenspring Station, MD; 17Merck Sharp & Dohme Corp., Whitehouse Station, NJ; 18Former employee of Merck Sharp & Dohme Corp., Whitehouse Station, NJ

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif

AASLD16.gif

AASLD17.gif